Our Story
A Mission Born from Scientific Vision
Ligandal was founded on a simple yet powerful principle: everyone deserves medicine that works at the molecular root of their disease. Andre Watson, our founder and CEO, established Ligandal with a vision for precision medicine targeting that allows for diseases to be approached at their molecular roots, with the aim of improving patient outcomes through accelerated translation of insights into cures.
Witnessing firsthand how years are lost to ineffective treatments and trial-and-error approaches, we set out to create technology that would fundamentally change how diseases are targeted and treated.
Today, our PDC (Peptide Direct Conjugate) technology, driven by LigandAI™ and Predictive Interactomics, represents the culmination of over 10 years of R&D directed towards that vision—precision medicine that targets disease at its molecular roots with unprecedented accuracy and efficiency.
"For decades, the industry has been constrained by imprecise drugs and an inability to guide our most advanced therapeutics to the disease sites that matter. Ligandal is building the enabling technology layer—a Delivery OS for precision medicine—that guides your therapies exactly where they need to go. This is the infrastructure that unlocks next-generation, molecularly and genomically precise therapeutics."
